OncoMatch/Clinical Trials/NCT06620848
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Is NCT06620848 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including HRS-4642 monotherapy and HRS-4642 and adebrelimab combination therapy for biliary tract cancer.
Treatment: HRS-4642 monotherapy · HRS-4642 and adebrelimab combination therapy — The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
progression or intolerance for one line of systemic therapy
Must have received: gemcitabine-based chemotherapy (gemcitabine) — adjuvant or neoadjuvant
adjuvant therapy or neoadjuvant therapy must include gemcitabine-based chemotherapy
Cannot have received: anti-tumor chemotherapy
Exception: within 4 weeks before the study drug administration
Prior anti-tumor chemotherapy within 4 weeks before the study drug administration
Cannot have received: small molecular targeted drugs
Exception: with a half-life of less than 5 or 7 days from the first medication
Small molecular targeted drugs (including oral targeted drugs for other clinical trials) with a half-life of less than 5 or 7 days from the first medication
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify